A U.K. primary care quality improvement project successfully reduced asthma rescue inhaler overuse by 63% through targeted interventions including patient education, clinician awareness initiatives and increased asthma reviews, demonstrating that proactive identification and management of at-risk patients significantly improves compliance with modern asthma treatment guidelines.
- Targeted interventions in primary care significantly reduced SABA inhaler overuse.
- Patients reporting poor asthma control symptoms declined by 51.4%, from 37 to 18 patients, indicating improved disease management.
- Excessive SABA use is linked to increased asthma exacerbations, hospital admissions, and mortality, making reduction critical.
Targeted interventions can significantly reduce overreliance on short-acting beta-2 agonist (SABA) inhalers among patients with asthma. That’s according to the paper, “Reducing Short-Acting Beta-2 Agonist (SABA) Overuse in Asthma: A Quality Improvement Project in Primary Care,” recently published in The Cureus Journal of Medical Science.
The paper details the results of a primary care quality improvement project designed to support national efforts to improve long-term asthma control and reduce preventable complications. Researchers at University College London Medical School evaluated prescribing clinics at a U.K. medical center serving approximately 7,670 patients. They conducted a two-cycle audit to identify patients who were potentially overusing SABA inhalers and assess compliance with updated national asthma management guidelines.
During the first audit cycle, 94 patients met the criteria for potential SABA overuse, which the study defined as having received at least two SABA inhalers within a 12-month period. More than half of these patients reported symptoms consistent with poor asthma control, indicating excessive reliance on rescue inhalers, which researchers said often coincided with inadequately managed disease.
Following the initial review, the clinics implemented several interventions, including patient education, reminders for asthma reviews, clinician awareness initiatives and increased encouragement of face-to-face asthma assessments. When researchers reassessed prescribing patterns one year later, the number of patients meeting the overuse criteria had fallen from 94 to 35, a reduction of 62.8%.
The number of patients reporting symptoms of poor asthma control also declined from 37 to 18, representing a 51.4% reduction. Researchers noted these findings suggest that proactive identification and management of at-risk patients can improve adherence to modern asthma treatment guidelines.
The project reflected a broader shift in asthma care. Investigators said that current recommendations from organizations including the U.K.’s National Institute for Health and Care Excellence, the British Thoracic Society and the Scottish Intercollegiate Guidelines Network encourage the use of anti-inflammatory reliever (AIR) and maintenance and reliever therapies (MART) over reliance on SABA-only treatment. They noted that recent evidence has linked excessive SABA use with increased asthma exacerbations, hospital admissions and mortality.
Researchers also identified barriers to adopting newer treatment approaches. Some patients declined medication changes because they preferred the rapid symptom relief provided by SABA inhalers, while others cited previous side effects or personal circumstances as reasons for maintaining their current treatment. These findings underscore the importance of ongoing patient engagement and education, investigators said.
Although the study was limited by its small sample size and follow-up challenges, investigators said that educational initiatives and changes to prescribing clinics can improve compliance with modern asthma guidelines and help identify patients at risk of poor disease control.
